Victor Domingos Lisita Rosa

Victor Domingos Lisita Rosa

Auto-generated profile, based on publicly available information

Victor Domingos Lisita Rosa

Centro Avançado de Diagnóstico da Mama (CORA), Teaching Hospital, Federal University of Goiás (UFG), Goiânia; Department of Medicine, Post-Graduation Program in Health Sciences, Federal University of Goiás (UFG), Goiânia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2023 in ESMO Open
Verified
Journal Article
Open access
LSLeonardo Ribeiro Soares
Leonardo Ribeiro Soares
MVMaysa Vilbert
Maysa Vilbert
VRV.D.L. Rosa
V.D.L. Rosa
JOJ.L. Oliveira
J.L. Oliveira
MDM.M. Deus
M.M. Deus
RFRuffo Frritas-Junior
Ruffo Frritas-Junior
Trastuzumab deruxtecan (T-DXd) has been shown to benefit progression-free survival and overall survival in patients with metastatic breast cancer (mBC) after progression on ≥1 human epidermal growth factor receptor 2 (HER2)-targeted therapies. However, interstitial lung disease (ILD) and cardiotoxicity are the most significant toxicities associated with T-DXd. Therefore, we conducted a systematic review and meta-analysis to assess the incidence and severity of these toxicities in mBC patients treated with T-DXd. We searched PubMed, Cochrane, and Scopus databases, and conferences websites for randomized clinical trials and nonrandomized studies of intervention including HER2-low or HER2-positive mBC patients who received at least one dose of T-DXd. Statistical analysis was carried out using R software. We included 15 studies comprising 1970 patients with a mean follow-up of 13.3 months. Median age ranged from 53 to 59 years, 61.9% were non-Asian, and 67.4% had hormone receptor-positive mBC. In a pooled analysis, the incidence of ILD was 11.7% [222 patients; 95% confidence interval (CI) 9.1% to 15.0%]. Patients receiving T-DXd dose of 6.4 mg/kg developed a significantly higher rate of ILD (22.7%) compared to those receiving a dose of 5.4 mg/kg (9.3%) (P < 0.01). Most cases of ILD (80.2%; 174/217 patients) were mild (grade 1 or 2). Grade 3 or 4 ILD was reported in 29 patients (13.4%), and grade 5 in 14 patients (6.4%). The incidence of decreased left ventricular ejection fraction (LVEF) was 1.95% (95% CI 0.65% to 3.73%), and the QT interval (QTi) prolongation was 7.77% (95% CI 2.74% to 20.11%). Most patients were asymptomatic, but four had LV dysfunction and heart failure (0.26%). In this meta-analysis of 1970 patients with mBC, treatment with T-DXd was associated with a 11.7% incidence of ILD, 7.7% incidence of prolonged QTi, and 1.9% incidence of reduced LVEF. Early detection and management of T-DXd-related toxicity by a multidisciplinary team may ultimately improve patient outcomes.

16 September 2021 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
VRVictor Domingos Lisita Rosa
Victor Domingos Lisita Rosa
ARANGELA ADAMSKI DA SILVA REIS
ANGELA ADAMSKI DA SILVA REIS
RARafael Ribeiro Alves
Rafael Ribeiro Alves
CACaroline Souza dos Anjos
Caroline Souza dos Anjos
RFRuffo Frritas-Junior
Ruffo Frritas-Junior

29 April 2020 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
LSLeonardo Ribeiro Soares
Leonardo Ribeiro Soares
VRVictor Domingos Lisita Rosa
Victor Domingos Lisita Rosa
RFRuffo Frritas-Junior
Ruffo Frritas-Junior

1 January 2017 in Journal of Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
VRVictor Lisita Rosa
Victor Lisita Rosa
FPFernanda Peria
Fernanda Peria
MBMariângela Ottoboni Brunaldi
Mariângela Ottoboni Brunaldi
The ampulla of Vater represents the epithelial junction of the main pancreatic duct and the distal bile duct, surrounded by the pancreatic head and duodenum parenchyma. Ampullary carcinoma can arise either from the intestinal epithelium or the epithelium covering the pancreatobiliary ducts. Many tumors develop from pre-existing adenomas, others evolve from precursor intraepithelial neoplasia supporting that two histological subtypes have different carcinogenesis. Thus, the question arises of classifying ampullary adenocarcinomas as the immunophenotypic pattern allowing a better understanding of the clinical implications of this neoplasm.

6 January 2025 in REVISTA FOCO
Verified
Journal Article
Open access
PDF file
NDNathan Muci Aguiar Damasio
Nathan Muci Aguiar Damasio
CVCarlos Vieira
Carlos Vieira
LPLaysa Barbosa Pontes
Laysa Barbosa Pontes
ASAnderson Garcia Silva
Anderson Garcia Silva
VRVictor Domingos Lisita Rosa
Victor Domingos Lisita Rosa
Rafael AlvesRafael Alves
Rafael Alves
Phase angle can be an indicator of membrane integrity and cell water distribution. Furthermore, phase angle can increase with training and, among women with breast cancer, it can be an indicator of survival. The aim of the study was to investigate the effects of resistance training and aerobic training on phase angle in breast cancer survivors. Searches were performed in the PubMed, Sicelo, and Google Scholar databases, considering publications between January 2014 and March 2024. Inclusion criteria were: clinical trials in English or Portuguese, which used resistance and/or aerobic training as an intervention for more than 8 weeks with breast cancer survivors and which measured the phase angle. Studies with other types of exercise, other chronic diseases, and other types of cancer were excluded. Five studies were included. These articles involved a total of 307 breast cancer survivors. No studies exclusively with aerobic training were found. Resistance or combined training was performed 2 to 5 times per week, mostly at moderate intensity and 30 to 90 minutes per session. Three of these studies showed significant increases in phase angle. Only one of the five studies reported being randomized and found no significant difference in phase angle. Conclusion: Resistance training and combined training may be effective in improving phase angle and cellular integrity in breast cancer patients or survivors.

1 January 2023
Verified
Conference Paper
Open access
VRVictor Domingos Lisita Rosa
Victor Domingos Lisita Rosa
PBPaulo Victor Rabelo Barbosa
Paulo Victor Rabelo Barbosa